The classic butyrate neuroprotection narrative likely depends on pharmacologic exposure sufficient for HDAC inhibition, not on the low systemic concentrations realistically achievable with diet or probiotics. This should be treated as a negative control or deprioritized mechanism rather than a leading therapeutic explanation for physiologic SCFA effects.
At realistic exposure levels, SCFAs are more likely to act as receptor-mediated endocrine signals than as direct neuronal epigenetic modulators. Activation of intestinal FFAR2/FFAR3 on L cells could raise GLP-1 signaling and secondarily improve neuronal stress resistance or proteostasis, but the current evidence supports mediation plausibility more than proven alpha-synuclein clearance.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
6/11
dimensions won
Direct neuronal HDAC inhibition is unlik
6/11
dimensions won
Physiological SCFAs may confer indirect
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.81
0.79
Evidence
0.71
0.60
Novelty
0.39
0.62
Feasibility
0.84
0.72
Impact
0.18
0.69
Druggability
0.28
0.80
Safety
0.65
0.71
Competition
0.44
0.56
Data
0.63
0.61
Reproducible
0.68
0.55
KG Connect
0.50
0.50
Score Breakdown
Dimension
Direct neuronal HDAC inhibitio
Physiological SCFAs may confer
Mechanistic
0.810
0.790
Evidence
0.710
0.600
Novelty
0.390
0.620
Feasibility
0.840
0.720
Impact
0.180
0.690
Druggability
0.280
0.800
Safety
0.650
0.710
Competition
0.440
0.560
Data
0.630
0.610
Reproducible
0.680
0.550
KG Connect
0.500
0.500
Evidence
Direct neuronal HDAC inhibition is unlikely to mediate thera
No evidence citations yet
Physiological SCFAs may confer indirect anti-synuclein benef
No evidence citations yet
Debate Excerpts
Direct neuronal HDAC inhibition is unlikely to med
4 rounds · quality: 0.63
Persona-Theorist
Below, I assume the key translational question is whether **physiologically achievable circulating SCFAs (roughly low-μM, especially for butyrate/propionate outside the colon)** can alter **α-synuclei...
Persona-Skeptic
**Overall**
The main weakness across all six hypotheses is the same: the cited literature mostly shows that SCFAs can change PD-like phenotypes under model-specific, often pharmacologic conditions, bu...
Persona-Domain Expert
Physiologic low-μM systemic SCFAs do not look like a standalone drug-ready route for driving meaningful brain α-syn clearance. The surviving ideas are narrower: a gut-first signaling effect, a GLP-1-l...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mechanism rather than direct brain exposure",
"d...
Physiological SCFAs may confer indirect anti-synuc
4 rounds · quality: 0.63
Persona-Theorist
Below, I assume the key translational question is whether **physiologically achievable circulating SCFAs (roughly low-μM, especially for butyrate/propionate outside the colon)** can alter **α-synuclei...
Persona-Skeptic
**Overall**
The main weakness across all six hypotheses is the same: the cited literature mostly shows that SCFAs can change PD-like phenotypes under model-specific, often pharmacologic conditions, bu...
Persona-Domain Expert
Physiologic low-μM systemic SCFAs do not look like a standalone drug-ready route for driving meaningful brain α-syn clearance. The surviving ideas are narrower: a gut-first signaling effect, a GLP-1-l...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mechanism rather than direct brain exposure",
"d...